XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026.
Rhea-AI Summary
XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a live webcast on March 18, 2026 at 8:00 AM ET to discuss results and provide a business update.
According to the company, the webcast will be accessible on the Investors "News & Events" page and a replay will be available for 30 days after the live event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – XOMA
On Mar 12, the day this news came out, XOMA closed 0.37% below the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Earnings date
- March 18, 2026
- Scheduled Q4 and full-year 2025 results release
- Webcast time
- 8:00 am Eastern Time
- Start time of March 18, 2026 results webcast
- Replay period
- 30 days
- Duration webcast replay will be available
Historical Context
-
Announced executive participation in March 2026 healthcare investor conferences.
-
Closed tender offer and acquisition of Generation Bio with cash and CVR package.
-
Long-tenured CFO stepped down and a new CFO was appointed.
-
Reworked mezagitamab royalty economics and gained rights to nine assets.
-
Declared quarterly cash dividends on Series A and Series B preferred shares.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update.
The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| Investor contact: | Media contact: |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty Corporation | KV Consulting & Management |
| +1-646-438-9754 | kathy@kathyvincent.com |
| juliane.snowden@xoma.com | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.